Drugs / Cytarabine
last change 8 days ago re-read 8 days ago

Cytarabine

Small molecule

Developed for
acute myeloid leukemia · leukemia · myelodysplastic syndrome · lymphoma · acute lymphoblastic leukemia · mantle cell lymphoma · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation
+152 more · diffuse large B-cell lymphoma · lymphoblastic lymphoma · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · childhood acute myeloid leukemia · adult acute monocytic leukemia · non-Hodgkin lymphoma · acute erythroid leukemia · acute myeloid leukemia, inv(16)(p13.1;q22) · primary central nervous system lymphoma · acute myeloid leukemia with minimal differentiation · Burkitt lymphoma · chronic myeloid leukemia · acute megakaryoblastic leukemia in adult · adult acute lymphoblastic leukemia · Hodgkins lymphoma · plasma cell myeloma · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia, del(5q31-q32) · acute promyelocytic leukemia · B-cell acute lymphoblastic leukemia · chronic myelomonocytic leukemia · myelodysplastic/myeloproliferative neoplasm · therapy related acute myeloid leukemia and myelodysplastic syndrome · acute leukemia · B-cell non-Hodgkin lymphoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · Langerhans cell histiocytosis · acute myeloid leukemia with multilineage dysplasia · childhood acute lymphoblastic leukemia · disease related to hematopoietic stem cell transplant · myeloid leukemia · neoplastic meningitis · peripheral T-cell lymphoma, not otherwise specified · acute basophilic leukemia · acute monocytic leukemia · acute myeloid leukemia, t(8;21)(q22; q22.1) · childhood acute megakaryoblastic leukemia · myelodysplastic syndrome with excess blasts · acute biphenotypic leukemia · acute myeloid leukemia, FLT3 internal tandem duplication · anaplastic large cell lymphoma · central nervous system neoplasm · HIV infectious disease · acute leukemia of ambiguous lineage · acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · childhood malignant neoplasm · childhood myelodysplastic syndrome · follicular lymphoma · hematopoietic and lymphoid cell neoplasm · high grade B-cell lymphoma · lymphoid leukemia · myelofibrosis · myeloproliferative neoplasm · plasma cell neoplasm · precursor B-cell acute lymphoblastic leukemia · refractory anemia with excess blasts in transformation · T lymphoblastic leukemia/lymphoma · T-cell acute lymphoblastic leukemia · acute myeloid leukemia with t(9;11)(p22;q23) · acute undifferentiated leukemia · B-cell childhood acute lymphoblastic leukemia · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · central nervous system non-hodgkin lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · classic Hodgkin lymphoma · erythroleukemia · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · juvenile myelomonocytic leukemia · mixed phenotype acute leukemia · mixed phenotype acute leukemia,T/myeloid · myelodysplastic syndrome associated with isolated del(5q) · myelodysplastic/myeloproliferative disease · neuroblastoma · nodular sclerosis classical Hodgkin lymphoma · Philadelphia-positive myelogenous leukemia · precursor lymphoblastic lymphoma/leukemia · refractory hematologic cancer · acquired polycythemia vera · acute myeloid leukemia, biallelic CEBPA gene mutation · acute myeloid leukemia, CEBPA gene mutation · acute myeloid leukemia, t(9;11)(p21.3;q23.3) · adult T-cell leukemia/lymphoma · aggressive B-cell non-Hodgkin lymphoma · atypical teratoid rhabdoid tumor · B-cell adult acute lymphocytic leukemia · B-lymphoblastic leukemia/lymphoma with hypodiploidy · bilineal acute myeloid leukemia · CD4+/CD56+ hematodermic neoplasm · central nervous system cancer · central nervous system leukemia · central nervous system vasculitis · cerebellar degeneration · childhood leukemia · childhood medulloblastoma · chronic inflammatory demyelinating polyradiculoneuropathy · embryonal tumor with multilayered rosettes · ependymoblastoma · essential thrombocythemia · glioblastoma · granulocytic sarcoma · hemopoietic proliferation · high-grade B-cell lymphoma double-hit/triple-hit · HIV-associated cancer · Lambert-Eaton myasthenic syndrome · leptomeningeal melanoma · leukemia, myeloid, accelerated-phase · malignant leptomeningeal tumor · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloepithelioma · melanoma · mixed phenotype acute leukemia, B/myeloid · myasthenia gravis · myeloid leukemia associated with down syndrome · myeloid neoplasm · myeloid sarcoma · myeloproliferative neoplasm, unclassifiable · neoplasm of mature B-cells · neoplasm of mediastinum · neuromyelitis optica · nodular lymphocyte predominant Hodgkin lymphoma · opsoclonus-myoclonus syndrome · pineoblastoma · plasma cell leukemia · post-transplant lymphoproliferative disease · primary brain neoplasm · primary mediastinal large B-cell lymphoma · progressive multifocal leukoencephalopathy · prostate cancer · Rasmussen subacute encephalitis · relapsing-remitting multiple sclerosis · retinoblastoma · Richter transformation · sarcoma · small intestine cancer · stiff-person syndrome · systemic lupus erythematosus · T-cell adult acute lymphocytic leukemia · T-cell leukemia · T-lymphoblastic lymphoma · urinary bladder cancer · urothelial carcinoma · Waldenstrom macroglobulinemia · acute myeloid leukemia with mutated NPM1 · core binding factor acute myeloid leukemia · metastatic malignant neoplasm in the brain · T-cell non-Hodgkin lymphoma
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Children's Oncology Group · PETHEMA Foundation · First Affiliated Hospital of Zhejiang University · The First Affiliated Hospital of Soochow University
+524 more · SWOG Cancer Research Network · St. Jude Children's Research Hospital · Institute of Hematology & Blood Diseases Hospital, China · European Organisation for Research and Treatment of Cancer - EORTC · Fred Hutchinson Cancer Center · Alliance for Clinical Trials in Oncology · Chinese PLA General Hospital · Memorial Sloan Kettering Cancer Center · Genzyme, a Sanofi Company · AbbVie · Jazz Pharmaceuticals · OHSU Knight Cancer Institute · University of Washington · Asan Medical Center · Dana-Farber Cancer Institute · GIMEMA Foundation · Hoffmann-La Roche · Navy General Hospital, Beijing · Seoul National University Hospital · Technical University Dresden · Wake Forest University Health Sciences · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Children's Hospital of Soochow University · Eastern Cooperative Oncology Group · French Innovative Leukemia Organisation · Goethe University · Roswell Park Cancer Institute · Severance Hospital · Shanghai Jiao Tong University School of Medicine · The Affiliated People's Hospital of Ningbo University · The Second People's Hospital of Huai'an · University of Nebraska · Washington University School of Medicine · 940 Hospital of the People's Liberation Army Joint Logistic Support Force · 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Amgen · Bayer · Beijing 302 Hospital · Cancer Research UK · Children's Cancer Group, China · City of Hope Medical Center · Deutsche Krebshilfe e.V., Bonn (Germany) · Eisai Inc. · Enzon Pharmaceuticals, Inc. · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · First Affiliated Hospital Xi'an Jiaotong University · Fondazione Italiana Linfomi - ETS · Hannover Medical School · Jining Medical University · Johann Wolfgang Goethe University Hospital · Lymphoma Study Association · Masonic Cancer Center, University of Minnesota · Medical Research Council · Nanjing Children's Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · Novartis · Peking University People's Hospital · Qilu Hospital of Shandong University · Shanghai Children's Medical Center · Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias · The General Hospital of Western Theater Command · University Hospital Freiburg · Virginia Commonwealth University · West China Second University Hospital · Xiangya Hospital of Central South University · Assistance Publique - Hôpitaux de Paris · Baylor College of Medicine · Beth Israel Deaconess Medical Center · Celgene Corporation · Changzhou No.2 People's Hospital · Columbia University · Cooperative Study Group A for Hematology · Duke University · First Hospital of China Medical University · all 530 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) DEPOCYT — 2007-04-19 fda.gov ↗
Approved EU (EMA) DepoCyte — 2001-07-11 europa.eu ↗
Approved US (FDA) CYTARABINE — 1969-06-17 fda.gov ↗

Trials 700 · started per year

today
US approved 1969
EU approved 2001
1
1
3
2
7
10
14
12
12
23
21
29
21
16
25
18
21
22
27
23
21
23
21
26
19
14
22
32
19
25
22
19
11
22
15
36
27
14
2
19681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT07059975 Oct 2025 → Oct 2028 expected childhood acute myeloid leukemia Joanna Yi Recruiting No outcome recorded
Phase 0 NCT06942039 Sep 2025 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 C17 Council Recruiting No outcome recorded
Phase 0 NCT00734773 Nov 2008 → ? central nervous system neoplasm, lymphoma Northwestern University Withdrawn No outcome recorded Stop: Business
Phase 0 NCT00572065 Feb 2008 → Dec 2009 myelofibrosis Weill Medical College of Cornell University Completed No outcome recorded
Phase 148 trials · 1 missed
Phase 1 NCT06474663 Jul 2025 refractory hematologic cancer M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT05476770 Nov 2022 → Nov 2025 overdue B-cell non-Hodgkin lymphoma, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, acute undifferentiated leukemia +3 Therapeutic Advances in Childhood Leukemia Consortium Recruiting No outcome recorded
Phase 1 NCT05453903 Oct 2022 → Oct 2026 expected acute myeloid leukemia Janssen Research & Development, LLC Active not recruiting No outcome recorded
Phase 1 NCT05342584 May 2022 → Dec 2028 expected acute myeloid leukemia, myelodysplastic syndrome Montefiore Medical Center Recruiting No outcome recorded
Phase 1 NCT04190550 Feb 2021 → Jun 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT04220684 Jun 2020 → Oct 2024 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Sumithira Vasu Completed No outcome recorded
Phase 1 NCT04196010 May 2020 → Oct 2021 acute myeloid leukemia University of Washington Terminated No outcome recorded
Phase 1 NCT03563560 May 2018 → Mar 2020 acute myeloid leukemia Sumitomo Pharma Co., Ltd. Completed No outcome recorded
Phase 1 NCT03519984 May 2018 → Nov 2020 Philadelphia-positive myelogenous leukemia, T-cell acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1 University of Southern California Terminated No outcome recorded
Phase 1 NCT03194932 Jul 2017 → Oct 2020 acute myeloid leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase 1/260 trials
Phase 1/2 NCT07451912 Sep 2025 → Sep 2027 expected acute myeloid leukemia, CEBPA gene mutation The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 1/2 NCT06561152 Feb 2025 → Oct 2027 expected acute myeloid leukemia Stanford University Recruiting No outcome recorded
Phase 1/2 NCT05849662 Oct 2024 → Dec 2028 expected CBL-related disorder, juvenile myelomonocytic leukemia, neurofibromatosis type 1 Therapeutic Advances in Childhood Leukemia Consortium Recruiting No outcome recorded
Phase 1/2 NCT06176027 Oct 2024 → Sep 2028 expected peripheral T-cell lymphoma, not otherwise specified Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 1/2 NCT05658640 Nov 2023 → Apr 2029 expected T-lymphoblastic lymphoma, acute lymphoblastic leukemia Princess Maxima Center for Pediatric Oncology Recruiting No outcome recorded
Phase 1/2 NCT04990102 May 2023 → Dec 2026 expected acute myeloid leukemia Georgetown University Recruiting No outcome recorded
Phase 1/2 NCT05893472 Apr 2023 → Apr 2024 acute myeloid leukemia ZePing Zhou Unknown No outcome recorded
Phase 1/2 NCT05192889 Aug 2022 → Jun 2024 overdue acute lymphoblastic leukemia St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT05100303 Dec 2021 → Nov 2022 acute myeloid leukemia CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT04956042 Aug 2021 → Dec 2023 acute myeloid leukemia CicloMed LLC Terminated No outcome recorded
Phase 2367 trials · 12 met primary · 4 missed
Phase 2 NCT07862517 Jan → Dec 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT05554419 Jan 2027 → Dec 2030 expected therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07763210 Sep 2026 → Mar 2028 expected diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma Vanderbilt-Ingram Cancer Center Recruiting No outcome recorded
Phase 2 NCT07423104 Aug 2026 → Feb 2029 expected acute myeloid leukemia University of Rochester Not yet recruiting No outcome recorded
Phase 2 NCT07677306 Jul 2026 → Dec 2027 expected myelodysplastic syndrome Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT07643103 Jun 2026 → May 2028 expected precursor B-cell acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07563179 Apr 2026 → Jun 2029 expected acute myeloid leukemia Shenzhen University General Hospital Recruiting No outcome recorded
Phase 2 NCT07514832 Apr 2026 → Apr 2028 expected acute myeloid leukemia Beijing 302 Hospital Recruiting No outcome recorded
Phase 2 NCT07227584 Apr 2026 → Jul 2030 expected acute lymphoblastic leukemia Dana-Farber Cancer Institute Not yet recruiting No outcome recorded
Phase 2 NCT07651475 Mar 2026 overdue acute myeloid leukemia Liping Dou Active not recruiting No outcome recorded
Show all 367 trials opens the full record — a long page
Phase 2/329 trials · 1 met primary
Phase 2/3 NCT07583888 May 2026 → Aug 2027 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2/3 NCT07651176 Mar 2026 → Dec 2029 expected acute myeloid leukemia First Affiliated Hospital of Zhejiang University Enrolling by invitation No outcome recorded
Phase 2/3 NCT07651163 Mar 2026 → Dec 2029 expected acute myeloid leukemia First Affiliated Hospital of Zhejiang University Enrolling by invitation No outcome recorded
Phase 2/3 NCT07168980 Jul 2025 → Jun 2030 expected B-cell non-Hodgkin lymphoma Children's Cancer Group, China Recruiting No outcome recorded
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT05805098 Mar 2023 → Mar 2025 overdue acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2/3 NCT05313958 Dec 2021 → Mar 2026 acute monocytic leukemia, childhood acute myeloid leukemia Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 2/3 NCT04216355 Jan 2020 → Dec 2021 myelodysplastic syndrome with excess blasts Fujian Medical University Unknown No outcome recorded
Phase 2/3 NCT04216771 Jan 2020 → May 2022 acute myeloid leukemia Fujian Medical University Unknown No outcome recorded
Phase 2/3 NCT03662087 Oct 2018 → Oct 2021 — Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 3116 trials · 8 met primary · 13 missed
Phase 3 NCT07132684 Aug 2025 → Aug 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 3 NCT07232134 Jul 2025 → Jul 2030 expected Down syndrome, acute myeloid leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting No outcome recorded
Phase 3 NCT06990321 Jun 2025 → Dec 2026 expected acute myeloid leukemia Yehui Tan Recruiting No outcome recorded
Phase 3 NCT06744504 Jan 2025 → Dec 2027 expected acute myeloid leukemia, t(8;21)(q22; q22.1) Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 3 NCT06673459 Dec 2024 → Nov 2029 expected T-cell leukemia The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 3 NCT06520163 Aug 2024 → Aug 2026 overdue non-Hodgkin lymphoma The Affiliated People's Hospital of Ningbo University Recruiting No outcome recorded
Phase 3 NCT06520176 Aug 2024 → Dec 2026 expected hemopoietic proliferation, plasma cell myeloma The Affiliated People's Hospital of Ningbo University Recruiting No outcome recorded
Phase 3 NCT06182592 Jan 2024 → Feb 2026 overdue acute myeloid leukemia CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06830421 Aug 2023 → Aug 2029 expected primary central nervous system lymphoma University Hospital Freiburg Recruiting No outcome recorded
Phase 3 NCT05177731 Mar 2022 → Feb 2024 overdue acute myeloid leukemia, chemotherapy-induced toxicity Chen Suning Active not recruiting Met primary
Show all 116 trials opens the full record — a long page
Phase 431 trials · 1 met primary · 1 missed
Phase 4 NCT06230055 Jan 2024 → Jan 2026 overdue Her2-receptor negative breast cancer, malignant leptomeningeal tumor Fudan University Recruiting No outcome recorded
Phase 4 NCT04083066 Sep 2019 → Apr 2023 primary central nervous system lymphoma Mingzhi Zhang Unknown No outcome recorded
Phase 4 NCT03873311 Sep 2019 → Dec 2022 myeloid leukemia Shenzhen Second People's Hospital Unknown No outcome recorded
Phase 4 NCT03500133 Oct 2017 → Oct 2027 expected Hodgkins lymphoma Hospital JP Garrahan Recruiting No outcome recorded
Phase 4 NCT02858804 Jan 2016 → Dec 2019 mantle cell lymphoma Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded
Phase 4 NCT01960192 Jun 2012 → Jun 2016 primary central nervous system lymphoma Mingzhi Zhang Unknown No outcome recorded
Phase 4 NCT02024308 Nov 2010 → Nov 2015 acute myeloid leukemia, t(8;21)(q22; q22.1) Changhai Hospital Unknown No outcome recorded
Phase 4 NCT01358201 May 2010 → Dec 2022 acute lymphoblastic leukemia PETHEMA Foundation Unknown No outcome recorded
Phase 4 NCT02894645 Oct 2008 → Oct 2018 childhood acute lymphoblastic leukemia National University Hospital, Singapore Unknown Met primary
Phase 4 NCT02036489 Jan 2008 → Dec 2019 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase not applicable45 trials · 1 missed
— NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
— NCT06697327 Feb → Aug 2025 overdue acute myeloid leukemia Anhui Medical University Enrolling by invitation No outcome recorded
— NCT07131059 May 2024 → May 2026 overdue acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT06329999 Feb 2024 → Dec 2025 overdue acute myeloid leukemia, myelodysplastic syndrome Ruijin Hospital Recruiting No outcome recorded
— NCT06232694 Jan 2024 → Dec 2027 expected acute myeloid leukemia The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
— NCT05941585 Aug 2023 → Jan 2025 acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded
— NCT05805072 May 2023 → Jun 2024 acute myeloid leukemia The First Affiliated Hospital of Soochow University Unknown No outcome recorded
— NCT05814718 Apr 2023 → Dec 2025 disease related to hematopoietic stem cell transplant First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
— NCT05681403 Jan 2023 → Dec 2026 expected lymphoma First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
— NCT06946407 Dec 2022 → Dec 2027 expected central nervous system non-hodgkin lymphoma FengYan Jin Recruiting No outcome recorded
Comparator or background therapy775 trials
Phase 0 NCT05528354 Background Jun 2022 → Dec 2025 disease related to hematopoietic stem cell transplant Zhejiang University Unknown No outcome recorded
Phase 0 NCT03568994 Background Jul 2018 → Sep 2020 acute myeloid leukemia Baylor College of Medicine Completed No outcome recorded
Phase 0 NCT01822015 Background Mar 2013 → Dec 2019 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +7 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 0 NCT01184885 Background Jul 2010 → Mar 2011 Burkitt lymphoma, acute lymphoblastic leukemia, adult T-cell leukemia/lymphoma, lymphoblastic lymphoma +1 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 1 NCT07444710 Background Oct 2026 → Sep 2027 expected mantle cell lymphoma National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Show all 775 trials opens the full record — a long page

Press releases naming this drug 18 releases

DateIssuerRelease
2024-11-12 Moleculin Biotech, Inc. Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) moleculin.com ↗
2023-10-02 Moleculin Biotech, Inc. Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
2023-05-02 Moleculin Biotech, Inc. Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
2023-03-01 Moleculin Biotech, Inc. Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
2022-12-21 Moleculin Biotech, Inc. Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
2022-05-05 Moleculin Biotech, Inc. Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
2021-03-30 Jazz Pharmaceuticals Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients jazzpharma.com ↗
2020-02-28 AbbVie AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML) abbvie.com ↗
2019-12-27 Mateon Therapeutics Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid Leukemia oncotelic.com ↗
2019-12-23 Mateon Therapeutics Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid Leukemia oncotelic.com ↗
2019-11-07 AVEO Pharmaceuticals, Inc. AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML aveooncology.com ↗
2019-04-01 AVEO Pharmaceuticals, Inc. AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML aveooncology.com ↗

Evidence & citations 35 cited values

Every value below carries the sentence it was read from. 1,482 sources stand behind the page.

FieldValueCited text
Known as cytarabine “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗
1358

“An alternative approach comprised of a shorter induction treatment with rituximab, HD-MTX and cytarabine (MARTA) followed by age-adjusted high-dose chemotherapy and autologous...” NCT06830421 ↗

“One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗

“Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗

“In a protocol of treatment of AML used in 1994 for adults with AML up to the age of 50 years, the Spanish CETLAM group showed a complete remission rate 75 % using the...” NCT01716793 ↗

“standard EAP mobilization chemotherapy (etoposide 75 mg/m² i.v. d1-2, cytarabine 200 mg/m² q12h i.v. d1-2; pegfilgrastim is administered subcutaneously on day 6 after...” NCT07848672 ↗

“Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is...” NCT06810791 ↗

“To determine the safety, tolerability and recommended phase II dose (RP2D) of Revumenib incombination with cytarabine and daunorubicin and Gemtuzumab ozogamicin (GO) in...” NCT07052994 ↗

“The goal of this clinical research study is to learn if clofarabine, when given in combination with ara-C (cytarabine), can help to improve the disease's response to therapy...” NCT00065143 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗

“SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a...” NCT06325748 ↗

Show 1,348 more sources

Known as 1-beta-d-arabinofuranosylcytosine “A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease.” PMID 16278404 ↗ Nov 2005
Known as Ara-C “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗
186

“This is a single-arm, open label phase II trial of the investigational agent, Ara-C (cytarabine), in patients diagnosed with hormone refractory prostate cancer whose disease...” NCT00480090 ↗

“BACKGROUND: The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia...” PMID 29615003 ↗ Apr 2018

“Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving...” PMID 17116939 ↗ Nov 2006

“This has also been the basis for successful application and granting of Orphan-Drug designation for cytarabine (Ara-C) liposome injection (trade name: DepoCyt) for the...” NCT01044966 ↗

“Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With...” NCT00180167 ↗

“Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on...” NCT00022490 ↗

“Patients receive high-dose cytarabine (ARA-C) IV twice daily on days 1-10; daunorubicin IV over 6 hours on days 1, 3, and 5; etoposide IV over 4 hours on days 1-5; and...” NCT00070174 ↗

“The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and...” NCT06468267 ↗

“Induction chemotherapy consisted fludarabine and cytarabine (ARAC) as a 24-hr CI without idarubicin (C-FLAG), which was compared with the results of C-FLAG with idarubicin...” PMID 25891993 ↗ May 2015

“During all 3 courses of the CODOX-M regimen, patients receive CNS prophylaxis comprising cytarabine (ARA-C) intrathecally (IT) on days 1 and 3, MTX IT on day 15, and oral CF...” NCT00040690 ↗

Show 176 more sources

Known as Ara-Cytarabine “Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7” NCT06345365 ↗
Known as ARABINOSYL-CYTOSINE “ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5” NCT00909168 ↗
Known as aracytin “L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)” NCT04475731 ↗
1

“* Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)” NCT02371161 ↗

Known as Aracytine “Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle...” NCT01389427 ↗
4

“Aracytine IV (3g/m²) day1 & day2” NCT00863460 ↗

NCT00689169 ↗

NCT00931138 ↗

NCT02896582 ↗

Known as Citarabine “Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗
1

“1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)” NCT04184505 ↗

Known as Cytarabine (A) “Cytarabine (A)” NCT01858922 ↗
Known as Cytarabine (ara-C) “Cytarabine (ara-C)” NCT06325748 ↗
1

“Cytarabine (Ara-c)” NCT01513603 ↗

Known as Cytarabine (Cytarabine hydrochloride) “Cytarabine (Cytarabine hydrochloride)” NCT05362942 ↗
Known as Cytarabine Hydrochloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT04220684 ↗
Known as Cytarabine Injection “Drug: Cytarabine Injection” NCT03569995 ↗
Known as cytarabine liposome “cytarabine liposome(50mg, q1-3w)” NCT06230055 ↗
Known as Cytosar “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗
Known as Cytosine arabinoside “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗
39

“This prospective interventional trial aims to test the efficacy and safety of the combination of methotrexate and cytosine arabinoside in adult LCH patients.” PMID 32423455 ↗ May 2020

“Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗

“Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia” NCT00086099 ↗

“Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).” NCT06578247 ↗

“Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).” NCT06841952 ↗

“high-dose BEAM (carmustine, etoposide, cytarabine, \[Ara-C, cytosine arabinoside\] and melphalan) chemotherapy” NCT01468311 ↗

“ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) chemotherapy was invented in 1994.” NCT00930605 ↗

“Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5” NCT00791947 ↗

“B - Carmustine (BCNU) E - Etoposide. A - Cytarabine (Ara-C, cytosine arabinoside) M - Melphalan” NCT00571493 ↗

“after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide” NCT01947322 ↗

Show 29 more sources

Known as cytosine arabinoside (ara-C) “cytosine arabinoside (ara-C)” NCT02670707 ↗
Known as Cytosine arabinosine hydrochloride “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗
Known as DepoCyt “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗
3

“Depocyt (Cytarabine Liposome Injection)” NCT00199108 ↗

“DepoCyt + Temozolomide” NCT00515788 ↗

NCT00964743 ↗

Known as DEPOCYT (Cytarabine Liposome Injection) “DEPOCYT® (Cytarabine Liposome Injection)” NCT01859819 ↗
Known as DepoCyte “Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL.” NCT01593488 ↗
1

“intrathecal liposomal cytarabine (DepoCyte®)” NCT00854867 ↗

Known as Depofoam encapsulated cytarabine “liposomal cytarabine (Depofoam encapsulated cytarabine; DTC 101)” NCT00003073 ↗
Known as DTC 101 “liposomal cytarabine (Depofoam encapsulated cytarabine; DTC 101)” NCT00003073 ↗
1

“intrathecal sustained release cytarabine (DTC101)” NCT00002704 ↗

Known as HiDAC “Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)” NCT01246752 ↗
1

“high-dose cytarabine (HIDAC)” NCT02633137 ↗

Known as IDAC “Intermediate-dose cytarabine (IDAC)” NCT02577406 ↗